Adjuvant immunotherapy: the sting in the tail.

Area of Science:

• Oncology
• Immunotherapy
• Endocrinology

Background:

• Adjuvant PD-1 inhibitor therapy is standard for resected Stage III/IV melanoma, reducing recurrence by 40-50%.
• Immune-related adverse events (irAEs) affect ~37% of patients, with 10-15% being severe (Grade III-IV).
• Endocrine toxicities are common, often irreversible, impacting thyroid, pituitary, adrenal glands, and glucose metabolism.

Purpose of the Study:

• To evaluate the balance between the benefits of adjuvant PD-1 inhibitors and their associated endocrine toxicities in melanoma patients.
• To inform clinical decision-making regarding immunotherapy use in patients with improved prognoses due to updated staging systems.

Main Methods:

• Review of pivotal trial data on PD-1 inhibitor efficacy and irAEs in melanoma.
• Analysis of endocrine toxicities, including thyroid dysfunction, hypophysitis, adrenalitis, and insulin-dependent diabetes mellitus.
• Consideration of updated AJCC staging (v8) and its impact on patient selection for adjuvant therapy.

Main Results:

• Adjuvant PD-1 inhibitors reduce melanoma recurrence by 40-50% but cause significant endocrine irAEs (e.g., thyroid toxicity 15-20%, IDDM 1%).
• Severe toxicities (Grade III-IV) occur in 10-15% of patients.
• Updated staging (v8) improves prognosis, potentially leading to immunotherapy use in lower-risk patients where the absolute benefit is modest.

Conclusions:

• The significant risk of irreversible endocrine toxicities necessitates careful consideration against the absolute benefit of recurrence reduction, particularly in patients with improved prognoses.
• Survivorship issues related to endocrine dysfunction (e.g., depression, hypogonadism, increased mortality from diabetes) are critical considerations.
• Clinical decisions must weigh the modest absolute benefit in some patient groups against the substantial burden of long-term toxicities.